Biotech Derivatives Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Derivatives

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (75)	4/9/1999 6:30:00 PM
From: sim1	Read Replies (2) of 555

<Not certain of timing relative to MOGN-relevant presentations> Found this wandering around their website. PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (P) Combinations of Established and New Antitumor Agents Apr 13 1999 1:15PM "Antitumor activity of MGI-114 in combination with DNA helicase inhibitors against pediatric tumor cell lines." Experimental Therapeutics I: Nucleosides, Oligonucleotides, Cyanoguanidines, and Other Low-Molecular-Weight Compounds Apr 12 1999 8:00AM "Efficacy of MGI 114 against the MRP-positive MV522 lung carcinoma xenograft." Apr 12 1999 8:00AM "Cytotoxic effects of MGI 114 are independent of tumor suppressor gene p53 and p21 expression." Novel Agents I Apr 11 1999 8:00AM "HMAF (6-hydroxymethylacylfulvene, MGI 114) induces chromosome destabilization in developing sea urchin embryos." Novel Agents II Apr 11 1999 1:15PM "Antitumor activity of MGI 114 against human ovarian and pancreatic tumor xenograft models." CLINICAL RESEARCH (P) CNS and Pediatric Malignancies Apr 13 1999 1:15PM "Antitumor activity of MGI 114 against pediatric rhabdomyosarcoma (RMS) tumor xenograft models." AACR website aacr.org AACR Annual Meeting Search aacr99.bluedot.com Daily calendar of events aacr.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next